Goje, I.-D.; Goje, G.-I.; Ordodi, V.L.; Ciobotaru, V.G.; Ivan, V.S.; Buzaș, R.; Tunea, O.; Bojin, F.; Lighezan, D.-F.
Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology. Pharmaceuticals 2025, 18, 681.
https://doi.org/10.3390/ph18050681
AMA Style
Goje I-D, Goje G-I, Ordodi VL, Ciobotaru VG, Ivan VS, Buzaș R, Tunea O, Bojin F, Lighezan D-F.
Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology. Pharmaceuticals. 2025; 18(5):681.
https://doi.org/10.3390/ph18050681
Chicago/Turabian Style
Goje, Iacob-Daniel, Greta-Ionela Goje, Valentin Laurențiu Ordodi, Valentina Gabriela Ciobotaru, Vlad Sabin Ivan, Roxana Buzaș, Oana Tunea, Florina Bojin, and Daniel-Florin Lighezan.
2025. "Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology" Pharmaceuticals 18, no. 5: 681.
https://doi.org/10.3390/ph18050681
APA Style
Goje, I.-D., Goje, G.-I., Ordodi, V. L., Ciobotaru, V. G., Ivan, V. S., Buzaș, R., Tunea, O., Bojin, F., & Lighezan, D.-F.
(2025). Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology. Pharmaceuticals, 18(5), 681.
https://doi.org/10.3390/ph18050681
